{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T03:02:05Z","timestamp":1790218925905,"version":"4.1.0"},"reference-count":98,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,6,4]],"date-time":"2024-06-04T00:00:00Z","timestamp":1717459200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Endocrinol."],"abstract":"<jats:sec><jats:title>Introduction<\/jats:title><jats:p>Lipodystrophy syndromes are rare diseases that can present with a broad range of symptoms. Delays in diagnosis are common, which in turn, may predispose to the development of severe metabolic complications and end-organ damage. Many patients with lipodystrophy syndromes are only diagnosed after significant metabolic abnormalities arise. Prompt action by clinical teams may improve disease outcomes in lipodystrophy syndromes. The aim of the Rapid Action Plan is to serve as a set of recommendations from experts that can support clinicians with limited experience in lipodystrophy syndromes.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>The Rapid Action Plan was developed using insights gathered through a series of advisory meetings with clinical experts in lipodystrophy syndromes. A skeleton template was used to facilitate interviews. A consensus document was developed, reviewed, and approved by all experts.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Lipodystrophy is a clinical diagnosis. The Rapid Action Plan discusses tools that can help diagnose lipodystrophy syndromes. The roles of clinical and family history, physical exam, patient and family member photos, routine blood tests, leptin levels, skinfold measurements, imaging studies, and genetic testing are explored. Additional topics such as communicating the diagnosis to the patients\/families and patient referrals are covered. A set of recommendations regarding screening and monitoring for metabolic diseases and end-organ abnormalities is presented. Finally, the treatment of lipodystrophy syndromes is reviewed.<\/jats:p><\/jats:sec><jats:sec><jats:title>Discussion<\/jats:title><jats:p>The Rapid Action Plan may assist clinical teams with the prompt diagnosis and holistic work-up and management of patients with lipodystrophy syndromes, which may improve outcomes for patients with this rare disease.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fendo.2024.1383318","type":"journal-article","created":{"date-parts":[[2024,6,4]],"date-time":"2024-06-04T05:20:46Z","timestamp":1717478446000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":23,"title":["A rapid action plan to improve diagnosis and management of lipodystrophy syndromes"],"prefix":"10.3389","volume":"15","author":[{"given":"Lindsay T.","family":"Fourman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Josivan Gomes","family":"Lima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vinaya","family":"Simha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Cappa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saif","family":"Alyaarubi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"Jr.","given":"Renan","family":"Montenegro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Baris","family":"Akinci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ferruccio","family":"Santini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2024,6,4]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra025261","article-title":"Acquired and inherited lipodystrophies","volume":"350","author":"Garg","year":"2004","journal-title":"N Engl J Med"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1097\/01.mol.0000217898.52197.18","article-title":"Lipodystrophy: lessons in lipid and energy metabolism","volume":"17","author":"Simha","year":"2006","journal-title":"Curr Opin Lipidol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.4158\/endp.19.1.v767575m65p5mr06","article-title":"The clinical approach to the detection of lipodystrophy - an aace consensus statement","volume":"19","author":"Handelsman","year":"2013","journal-title":"Endocr Pract"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2016\u20132466","article-title":"The diagnosis and management of lipodystrophy syndromes: A multi-society practice guideline","volume":"101","author":"Brown","year":"2016","journal-title":"J Clin Endocrinol Metab"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1038\/nrendo.2015.123","article-title":"Congenital generalized lipodystrophies\u2013new insights into metabolic dysfunction","volume":"11","author":"Patni","year":"2015","journal-title":"Nat Rev Endocrinol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1016\/j.ecl.2016.06.012","article-title":"Lipodystrophy syndromes","volume":"45","author":"Hussain","year":"2016","journal-title":"Endocrinol Metab Clin North Am"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1097\/00005792\u2013200303000\u201300007","article-title":"Clinical features and metabolic derangements in acquired generalized lipodystrophy: case reports and review of the literature","volume":"82","author":"Misra","year":"2003","journal-title":"Med (Baltimore)"},{"key":"B8","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1097\/01.md.0000111061.69212.59","article-title":"Clinical features and metabolic and autoimmune derangements in acquired partial lipodystrophy: report of 35 cases and review of the literature","volume":"83","author":"Misra","year":"2004","journal-title":"Med (Baltimore)"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1016\/j.lpm.2021.104071","article-title":"Familial partial lipodystrophy syndromes","volume":"50","author":"Fernandez-Pombo","year":"2021","journal-title":"Presse Med"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1006\/mgme.2000.3092","article-title":"Familial partial lipodystrophy: A monogenic form of the insulin resistance syndrome","volume":"71","author":"Hegele","year":"2000","journal-title":"Mol Genet Metab"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1016\/j.ando.2012.04.010","article-title":"How to diagnose a lipodystrophy syndrome","volume":"73","author":"Vantyghem","year":"2012","journal-title":"Ann Endocrinol (Paris)"},{"key":"B12","doi-asserted-by":"publisher","first-page":"71","DOI":"10.2337\/db21\u20131086","article-title":"Characterization and clinical association of autoantibodies against perilipin 1 in patients with acquired generalized lipodystrophy","volume":"72","author":"Corvillo","year":"2023","journal-title":"Diabetes"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1016\/j.lpm.2021.104073","article-title":"Autoimmunity in lipodystrophy syndromes","volume":"50","author":"Ceccarini","year":"2021","journal-title":"Presse Med"},{"key":"B14","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1007\/s11892\u2013018-1099\u20139","article-title":"Phenotypic and genetic characteristics of lipodystrophy: pathophysiology, metabolic abnormalities, and comorbidities","volume":"18","author":"Akinci","year":"2018","journal-title":"Curr Diabetes Rep"},{"key":"B15","volume-title":"Lipodystrophy Syndromes: Presentation and Treatment","author":"Akinci","year":"2000"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1530\/EJE-18\u20130847","article-title":"Geoffrey harris prize lecture 2018: novel pathways regulating neuroendocrine function, energy homeostasis and metabolism in humans","volume":"180","author":"Papathanasiou","year":"2019","journal-title":"Eur J Endocrinol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2003\u2013031868","article-title":"Effects of exogenous leptin on satiety and satiation in patients with lipodystrophy and leptin insufficiency","volume":"89","author":"McDuffie","year":"2004","journal-title":"J Clin Endocrinol Metab"},{"key":"B18","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1186\/s13052\u2013020-00916\u20132","article-title":"Metreleptin for the treatment of progressive encephalopathy with\/without lipodystrophy (Peld) in a child with progressive myoclonic epilepsy: A case report","volume":"46","author":"Pedicelli","year":"2020","journal-title":"Ital J Pediatr"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2018\u201302730","article-title":"Comorbidities and survival in patients with lipodystrophy: an international chart review study","volume":"104","author":"Akinci","year":"2019","journal-title":"J Clin Endocrinol Metab"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1097\/MOL.0b013e32832d4a33","article-title":"Inherited lipodystrophies and hypertriglyceridemia","volume":"20","author":"Simha","year":"2009","journal-title":"Curr Opin Lipidol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1161\/01.cir.103.18.2225","article-title":"Premature atherosclerosis associated with monogenic insulin resistance","volume":"103","author":"Hegele","year":"2001","journal-title":"Circulation"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1016\/j.pathol.2018.11.004","article-title":"Lipodystrophies, dyslipidaemias and atherosclerotic cardiovascular disease","volume":"51","author":"Hussain","year":"2019","journal-title":"Pathology"},{"key":"B23","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1007\/s40618-018-0887-z","article-title":"Diagnosis and treatment of lipodystrophy: A step-by-step approach","volume":"42","author":"Araujo-Vilar","year":"2019","journal-title":"J Endocrinol Invest"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgac079","article-title":"Approach to the patient with lipodystrophy","volume":"107","author":"Fourman","year":"2022","journal-title":"J Clin Endocrinol Metab"},{"key":"B25","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1080\/17446651.2020.1735360","article-title":"Diagnostic strategies and clinical management of lipodystrophy","volume":"15","author":"Foss-Freitas","year":"2020","journal-title":"Expert Rev Endocrinol Metab"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1186\/1758\u20135996-4\u201340","article-title":"Body composition study by dual-energy X-ray absorptiometry in familial partial lipodystrophy: finding new tools for an objective evaluation","volume":"4","author":"Valerio","year":"2012","journal-title":"Diabetol Metab Syndr"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.2337\/dc24-S004","article-title":"Comprehensive medical evaluation and assessment of comorbidities: standards of care in diabetes-2024","volume":"47","year":"2024","journal-title":"Diabetes Care"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.2337\/dc24-S006","article-title":"Glycemic goals and hypoglycemia: standards of care in diabetes-2024","volume":"47","year":"2024","journal-title":"Diabetes Care"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.2337\/dc24-S010","article-title":"Cardiovascular disease and risk management: standards of care in diabetes-2024","volume":"47","year":"2024","journal-title":"Diabetes Care"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1002\/hep.20672","article-title":"Leptin reverses nonalcoholic steatohepatitis in patients with severe lipodystrophy","volume":"41","author":"Javor","year":"2005","journal-title":"Hepatology"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pgen.1000874","article-title":"Fatal cardiac arrhythmia and long-qt syndrome in a new form of congenital generalized lipodystrophy with muscle rippling (Cgl4) due to ptrf-cavin mutations","volume":"6","author":"Rajab","year":"2010","journal-title":"PloS Genet"},{"key":"B32","doi-asserted-by":"publisher","first-page":"e63533","DOI":"10.1002\/ajmg.a.63533","article-title":"Metabolic and other morbid complications in congenital generalized lipodystrophy type 4","volume":"194","author":"Akinci","year":"2024","journal-title":"Am J Med Genet A"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1111\/cen.14426","article-title":"Cardiac phenotype in familial partial lipodystrophy","volume":"94","author":"Eldin","year":"2021","journal-title":"Clin Endocrinol (Oxf)"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1046\/j.1464-5491.2002.00796.x","article-title":"Post-mortem findings in familial partial lipodystrophy, dunnigan variety","volume":"19","author":"Haque","year":"2002","journal-title":"Diabetes Med"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1111\/dom.15061","article-title":"Clinical features of generalized lipodystrophy in Turkey: A cohort analysis","volume":"25","author":"Yildirim Simsir","year":"2023","journal-title":"Diabetes Obes Metab"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.2337\/cd16\u20130002","article-title":"Cardiac manifestations of congenital generalized lipodystrophy","volume":"34","author":"Sanon","year":"2016","journal-title":"Clin Diabetes"},{"key":"B37","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1111\/cen.13732","article-title":"Renal complications of lipodystrophy: A closer look at the natural history of kidney disease","volume":"89","author":"Akinci","year":"2018","journal-title":"Clin Endocrinol (Oxf)"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1016\/s0022\u20133476(79)80087\u20136","article-title":"Congenital lipodystrophy. Ii. Association with polycystic ovarian disease","volume":"95","author":"Huseman","year":"1979","journal-title":"J Pediatr"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1177\/014107680109400510","article-title":"Unwin RJ. Partial lipodystrophy, polycystic ovary syndrome and proteinuria: A common link to insulin resistance","volume":"94","author":"Blackwell","year":"2001","journal-title":"J R Soc Med"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1210\/jcem.87.7.8591","article-title":"Effect of leptin replacement on pituitary hormone regulation in patients with severe lipodystrophy","volume":"87","author":"Oral","year":"2002","journal-title":"J Clin Endocrinol Metab"},{"key":"B41","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/j.biochi.2004.11.014","article-title":"Longevity, lipotoxicity and leptin: the adipocyte defense against feasting and famine","volume":"87","author":"Unger","year":"2005","journal-title":"Biochimie"},{"key":"B42","doi-asserted-by":"publisher","first-page":"1994","DOI":"10.2337\/diabetes.54.7.1994","article-title":"Long-term efficacy of leptin replacement in patients with generalized lipodystrophy","volume":"54","author":"Javor","year":"2005","journal-title":"Diabetes"},{"key":"B43","doi-asserted-by":"crossref","DOI":"10.1007\/978-4-431-55651-0_14","article-title":"Translational Research of Leptin in Lipodystrophy and Its Related Diseases","volume-title":"Innovative Medicine: Basic Research and Development","author":"Ebihara","year":"2015"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2012\u20131872","article-title":"Functional magnetic resonance imaging analysis of food-related brain activity in patients with lipodystrophy undergoing leptin replacement therapy","volume":"97","author":"Aotani","year":"2012","journal-title":"J Clin Endocrinol Metab"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2004\u20131232","article-title":"Leptin and appetite control in lipodystrophy","volume":"89","author":"Ahima","year":"2004","journal-title":"J Clin Endocrinol Metab"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1038\/sj.ijo.0801442","article-title":"Psychometric properties and factor structure of the three-factor eating questionnaire (Tfeq) in obese men and women. Results from the swedish obese subjects (Sos) study","volume":"24","author":"Karlsson","year":"2000","journal-title":"Int J Obes Relat Metab Disord"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1007\/s40519\u2013019-00716\u20136","article-title":"Psychopathological and psychiatric evaluation of patients affected by lipodystrophy","volume":"25","author":"Calabro","year":"2020","journal-title":"Eat Weight Disord"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1186\/s13023-023-03004-w","article-title":"Impact of lipodystrophy on health-related quality of life: the qualip study","volume":"19","author":"Demir","year":"2024","journal-title":"Orphanet J Rare Dis"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2023.1190363","article-title":"Is it possible to achieve an acceptable disease control by dietary therapy alone in berardinelli seip type 1? Experience from a case report","volume":"14","author":"Cecchetti","year":"2023","journal-title":"Front Endocrinol (Lausanne)"},{"key":"B50","unstructured":""},{"key":"B51","unstructured":""},{"key":"B52","unstructured":""},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.2337\/dc24-S009","article-title":"Pharmacologic approaches to glycemic treatment: standards of care in diabetes-2024","volume":"47","year":"2024","journal-title":"Diabetes Care"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.7326\/0003\u20134819-133\u20134-200008150\u201300009","article-title":"Efficacy and safety of troglitazone in the treatment of lipodystrophy syndromes","volume":"133","author":"Arioglu","year":"2000","journal-title":"Ann Intern Med"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.2337\/db17\u20131236","article-title":"A pharmacogenetic approach to the treatment of patients with pparg mutations","volume":"67","author":"Agostini","year":"2018","journal-title":"Diabetes"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1016\/j.diabet.2009.01.001","article-title":"Long-term improvement of metabolic control with pioglitazone in a woman with diabetes mellitus related to dunnigan syndrome: A case report","volume":"35","author":"Collet-Gaudillat","year":"2009","journal-title":"Diabetes Metab"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1007\/s00125\u2013013-2926\u20139","article-title":"Thiazolidinediones partially reverse the metabolic disturbances observed in bscl2\/seipin-deficient mice","volume":"56","author":"Prieur","year":"2013","journal-title":"Diabetologia"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1136\/bcr-2018\u2013225553","article-title":"Acquired generalised lipodystrophy and type 1 diabetes mellitus in a child: A rare and implacable association","volume":"2018","author":"Kumar","year":"2018","journal-title":"BMJ Case Rep"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1210\/jcemcr\/luae009","article-title":"Spontaneous remission of acquired generalized lipodystrophy presenting in the postpartum period","volume":"2","author":"Bhatia","year":"2024","journal-title":"JCEM Case Rep"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2021.690996","article-title":"Case report: metreleptin and sglt2 inhibitor combination therapy is effective for acquired incomplete lipodystrophy","volume":"12","author":"Nagayama","year":"2021","journal-title":"Front Endocrinol (Lausanne)"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1016\/j.eprac.2022.03.006","article-title":"Clinical effects of sodium-glucose transporter type 2 inhibitors in patients with partial lipodystrophy","volume":"28","author":"Bansal","year":"2022","journal-title":"Endocr Pract"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.2337\/diacare.28.5.1240","article-title":"The use of U-500 in patients with extreme insulin resistance","volume":"28","author":"Cochran","year":"2005","journal-title":"Diabetes Care"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1002\/oby.23049","article-title":"The metabolic equivalent bmi in patients with familial partial lipodystrophy (Fpld) compared with those with severe obesity","volume":"29","author":"Koo","year":"2021","journal-title":"Obes (Silver Spring)"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1111\/dme.13527","article-title":"Insulin secretory defect in familial partial lipodystrophy type 2 and successful long-term treatment with a glucagon-like peptide 1 receptor agonist","volume":"34","author":"Banning","year":"2017","journal-title":"Diabetes Med"},{"key":"B65","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1186\/s13256\u2013016-1175\u20131","article-title":"Glucagon-like peptide-1 analogues - an efficient therapeutic option for the severe insulin resistance of lipodystrophic syndromes: two case reports","volume":"11","author":"Oliveira","year":"2017","journal-title":"J Med Case Rep"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.1007\/s12020\u2013020-02223\u20136","article-title":"Glp-1 receptor agonists and pancreatic safety concerns in type 2 diabetic patients: data from cardiovascular outcome trials","volume":"68","author":"Cao","year":"2020","journal-title":"Endocrine"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2023.19574","article-title":"Risk of gastrointestinal adverse events associated with glucagon-like peptide-1 receptor agonists for weight loss","volume":"330","author":"Sodhi","year":"2023","journal-title":"JAMA"},{"key":"B68","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1056\/NEJMoa1812792","article-title":"Cardiovascular risk reduction with icosapent ethyl for hypertriglyceridemia","volume":"380","author":"Bhatt","year":"2019","journal-title":"N Engl J Med"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2020.22258","article-title":"Effect of high-dose omega-3 fatty acids vs corn oil on major adverse cardiovascular events in patients at high cardiovascular risk: the strength randomized clinical trial","volume":"324","author":"Nicholls","year":"2020","journal-title":"JAMA"},{"key":"B70","doi-asserted-by":"publisher","first-page":"1063","DOI":"10.1001\/jama.2021.2909","article-title":"Omega-3 fatty acids and atrial fibrillation","volume":"325","author":"Curfman","year":"2021","journal-title":"JAMA"},{"key":"B71","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1097\/MCO.0000000000000907","article-title":"Do omega-3 fatty acids increase risk of atrial fibrillation","volume":"26","author":"Bork","year":"2023","journal-title":"Curr Opin Clin Nutr Metab Care"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.1016\/j.eprac.2022.03.010","article-title":"American association of clinical endocrinology clinical practice guideline for the diagnosis and management of nonalcoholic fatty liver disease in primary care and endocrinology clinical settings: co-sponsored by the american association for the study of liver diseases (Aasld)","volume":"28","author":"Cusi","year":"2022","journal-title":"Endocr Pract"},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.2337\/dc24-S011","article-title":"Chronic kidney disease and risk management: standards of care in diabetes-2024","volume":"47","year":"2024","journal-title":"Diabetes Care"},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.1053\/j.ajkd.2012.07.017","article-title":"Management of hyperglycemia, dyslipidemia, and albuminuria in patients with diabetes and ckd: A systematic review for a kdoqi clinical practice guideline","volume":"60","author":"Slinin","year":"2012","journal-title":"Am J Kidney Dis"},{"key":"B75","doi-asserted-by":"publisher","DOI":"10.1097\/GME.0000000000002028","article-title":"The 2022 hormone therapy position statement of the north american menopause society","volume":"29","year":"2022","journal-title":"Menopause"},{"key":"B76","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgad463","article-title":"Recommendations from the 2023 international evidence-based guideline for the assessment and management of polycystic ovary syndrome","volume":"108","author":"Teede","year":"2023","journal-title":"J Clin Endocrinol Metab"},{"key":"B77","doi-asserted-by":"publisher","DOI":"10.2337\/dc07\u20130025","article-title":"Dual-energy X-ray absorptiometry study of body composition in patients with lipodystrophy","volume":"30","author":"Valerio","year":"2007","journal-title":"Diabetes Care"},{"key":"B78","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgaa137","article-title":"Diagnostic value of anthropometric measurements for familial partial lipodystrophy, dunnigan variety","volume":"105","author":"Vasandani","year":"2020","journal-title":"J Clin Endocrinol Metab"},{"key":"B79","doi-asserted-by":"publisher","first-page":"698","DOI":"10.1111\/cen.13311","article-title":"Spectrum of disease associated with partial lipodystrophy: lessons from a trial cohort","volume":"86","author":"Ajluni","year":"2017","journal-title":"Clin Endocrinol (Oxf)"},{"key":"B80","doi-asserted-by":"publisher","DOI":"10.2337\/dc18\u20130978","article-title":"\"Fat shadows\" from dxa for the qualitative assessment of lipodystrophy: when a picture is worth a thousand numbers","volume":"41","author":"Meral","year":"2018","journal-title":"Diabetes Care"},{"key":"B81","doi-asserted-by":"publisher","DOI":"10.1152\/physrev.00032.2020","article-title":"Lipodistrophy: A paradigm for understanding the consequences of \"Overloading\" Adipose tissue","volume":"101","author":"Lim","year":"2021","journal-title":"Physiol Rev"},{"key":"B82","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgad063","article-title":"Pelvis magnetic resonance imaging to diagnose familial partial lipodystrophy","volume":"108","author":"Adiyaman","year":"2023","journal-title":"J Clin Endocrinol Metab"},{"key":"B83","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2003\u2013030835","article-title":"Phenotypic heterogeneity in body fat distribution in patients with congenital generalized lipodystrophy caused by mutations in the agpat2 or seipin genes","volume":"88","author":"Simha","year":"2003","journal-title":"J Clin Endocrinol Metab"},{"key":"B84","doi-asserted-by":"publisher","DOI":"10.5152\/dir.2017.17019","article-title":"Determining residual adipose tissue characteristics with mri in patients with various subtypes of lipodystrophy","volume":"23","author":"Altay","year":"2017","journal-title":"Diagn Interv Radiol"},{"key":"B85","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1016\/j.mric.2010.08.013","article-title":"Quantification of liver fat with magnetic resonance imaging","volume":"18","author":"Reeder","year":"2010","journal-title":"Magn Reson Imaging Clin N Am"},{"key":"B86","doi-asserted-by":"publisher","DOI":"10.1210\/js.2019\u201300103","article-title":"Advanced lipoprotein analysis shows atherogenic lipid profile that improves after metreleptin in patients with lipodystrophy","volume":"3","author":"Kinzer","year":"2019","journal-title":"J Endocr Soc"},{"key":"B87","doi-asserted-by":"publisher","DOI":"10.1097\/MED.0000000000000695","article-title":"Advances in the care of lipodystrophies","volume":"29","author":"Shamsudeen","year":"2022","journal-title":"Curr Opin Endocrinol Diabetes Obes"},{"key":"B88","doi-asserted-by":"publisher","DOI":"10.1007\/s12020\u2013018-1589\u20131","article-title":"Long-term effectiveness and safety of metreleptin in the treatment of patients with generalized lipodystrophy","volume":"60","author":"Brown","year":"2018","journal-title":"Endocrine"},{"key":"B89","doi-asserted-by":"publisher","first-page":"659","DOI":"10.4172\/2155\u20136156.1000659","article-title":"Efficacy and safety of metreleptin in patients with partial lipodystrophy: lessons from an expanded access program","volume":"7","author":"Ajluni","year":"2016","journal-title":"J Diabetes Metab"},{"key":"B90","doi-asserted-by":"publisher","DOI":"10.1007\/s12020\u2013019-01862\u20138","article-title":"Long-term effectiveness and safety of metreleptin in the treatment of patients with partial lipodystrophy","volume":"64","author":"Oral","year":"2019","journal-title":"Endocrine"},{"key":"B91","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa012437","article-title":"Leptin-replacement therapy for lipodystrophy","volume":"346","author":"Oral","year":"2002","journal-title":"N Engl J Med"},{"key":"B92","doi-asserted-by":"publisher","DOI":"10.1172\/JCI15001","article-title":"Leptin reverses insulin resistance and hepatic steatosis in patients with severe lipodystrophy","volume":"109","author":"Petersen","year":"2002","journal-title":"J Clin Invest"},{"key":"B93","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2013.02.007","article-title":"The liver diseases of lipodystrophy: the long-term effect of leptin treatment","volume":"59","author":"Safar Zadeh","year":"2013","journal-title":"J Hepatol"},{"key":"B94","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2003\u2013032140","article-title":"Proteinuric nephropathy in acquired and congenital generalized lipodystrophy: baseline characteristics and course during recombinant leptin therapy","volume":"89","author":"Javor","year":"2004","journal-title":"J Clin Endocrinol Metab"},{"key":"B95","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2019\u201300200","article-title":"Effects of metreleptin on proteinuria in patients with lipodystrophy","volume":"104","author":"Lee","year":"2019","journal-title":"J Clin Endocrinol Metab"},{"key":"B96","doi-asserted-by":"publisher","DOI":"10.1007\/s12020\u2013014-0450\u20134","article-title":"Recombinant human leptin treatment in genetic lipodystrophic syndromes: the long-term spanish experience","volume":"49","author":"Araujo-Vilar","year":"2015","journal-title":"Endocrine"},{"key":"B97","doi-asserted-by":"publisher","first-page":"586","DOI":"10.1530\/endoabs.63.P586","article-title":"Savage DB real-world experience of generalized and partial lipodystrophy patients enrolled in the metreleptin early access program","volume":"63","author":"Cook","year":"2019","journal-title":"Endocrine Abstracts"},{"key":"B98","doi-asserted-by":"publisher","DOI":"10.1111\/dom.14726","article-title":"Therapeutic indications and metabolic effects of metreleptin in patients with lipodystrophy syndromes: real-life experience from a national reference network","volume":"24","author":"Mosbah","year":"2022","journal-title":"Diabetes Obes Metab"}],"container-title":["Frontiers in Endocrinology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2024.1383318\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,17]],"date-time":"2024-06-17T12:46:17Z","timestamp":1718628377000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2024.1383318\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6,4]]},"references-count":98,"alternative-id":["10.3389\/fendo.2024.1383318"],"URL":"https:\/\/doi.org\/10.3389\/fendo.2024.1383318","relation":{},"ISSN":["1664-2392"],"issn-type":[{"value":"1664-2392","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,6,4]]},"article-number":"1383318"}}